In Brief: Casgevy for Beta Thalassemia

descriptionPublicationkeyboard_double_arrow_right Article 13 May 2024Publisher:The Medical Letter, Inc.Journal:The Medical Letter on Drugs and Therapeutics, volume 66, pages 79-79 (eissn: 1523-2859,

doi: 10.58347/tml.2024.1702d

pmid: 38696313

In Brief: Casgevy for Beta Thalassemia

- Summary
- Subjects
- Metrics

Abstract

Exagamglogene autotemcel (Casgevy – Vertex), a cell-based gene therapy recently approved for treatment of sickle cell disease1, has now been approved by the FDA for treatment of patients ≥12 years old with transfusion-dependent beta thalassemia.

Keywords

beta-Thalassemia, Humans, Iron Chelating Agents

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average